# US 2013/0158091 A1 · Polymorphs of saxagliptin hydrochloride and processes for preparing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158091 A1
- Document ID: US20130158091A1
- Status: Published application
- Kind: A1
- Application number: 13/767,949
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2010-10-04
- Inventors: Marina MARINKOVIC; Marina RATKAJ; Oliver FRANKOVIC; Tina MUNDORFER
- Web page: https://patentgrep.com/patent/US20130158091A1

## CPC

- C07D 209/52: condensed with a ring other than six-membered
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

Amorphous Saxagliptin hydrochloride.

### Claim 20 (depends on 19)

The amorphous Saxagliptin hydrochloride of claim 19, characterized by an X-ray powder diffraction pattern substantially as depicted in FIG. 17.

### Claim 21 (depends on 19, 20)

A pharmaceutical composition comprising the amorphous Saxagliptin hydrochloride according to any one of claims 19 and 20, and at least one pharmaceutically acceptable excipient.

### Claim 22 (depends on 21)

A method of treating a patient suffering from type 2 diabetes, comprising administering a pharmaceutical composition according to claim 21.